Preferred Label : Anti-PD-1 Antibody/IL-18 Variant Immunocytokine BPT567;
NCIt synonyms : Anti-PD-1 Monoclonal Antibody LZM009/IL-18 Variant Immunocytokine BPT567; Lipustobart/IL-18 Variant Immunocytokine BPT567; Anti-PD-1 Antibody/IL-18 Variant Fusion Protein BPT567; PD-1-targeting IL-18 Variant BPT567;
NCIt definition : An immunocytokine composed of lipustobart, an antibody directed against the human
negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1;
PDCD1; CD279), site-specifically conjugated to a human interleukin-18 (IL-18) variant,
with potential immunostimulating and antineoplastic activities. Upon administration
of anti-PD-1 antibody/IL-18 variant immunocytokine BPT567, lipustobart targets and
binds to PD-1-expressing T-cells in the tumor microenvironment (TME). This prevents
the activation of PD-1 and its downstream signaling pathways, leading to the activation
of both T-cells and T-cell-mediated immune responses against tumor cells. The IL-18
variant binds to and activates the IL-18 receptor on the PD-1-expressing T-cells in
the TME, which activates T-cells and natural killer (NK) cells and induces the secretion
of interferon-gamma (IFNg). This potentiates the immune response against tumor cells.
PD-1 is a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on
activated T-cells that negatively regulates T-cell activation and effector function
when activated by its ligands. PD-1 plays an important role in tumor evasion from
host immunity. IL-18 is a proinflammatory cytokine that belongs to the interleukin-1
(IL-1) superfamily of cytokines. The IL-18 variant is engineered to preferably bind
to the IL-18 receptor and not IL-18 binding protein (IL-18BP), which acts as a decoy
receptor of IL-18 and prevents the activation of IL-18 receptor.;
Molecule name : BPT 567; BPT-567;
Origin ID : C216238;
concept_is_in_subset
- has_target
